In this regard, intratumoral and IV therapies that utilize the nonpathogenic oncolytic measles virus Emonston strain (MV-Edm) showed significant inhibition of tumor growth, survival benefits, and tumor regression in susceptible mice via CD46 targeting. The gene discussed is CD46; the disease is neoplasm.